bioRxivMolecular BiologyPreprint
Balancing Activation and Repression: CoREST-p300 Antagonism Controls Retinoic Acid-Driven Differentiation in AML
Mina Masoumeh TayariiD, Helena Gomes Dos SantosiD, Sadat DokaneheifardiD, Samuel D. WhedoniD, Monica Valencia, Arigela HarikumariD, Felipe BeckedorffiD, Justin M. WattsiD, Philip A. ColeiD, Ramin ShiekhattariD
Abstract
The histone demethylase KDM1A (LSD1), a component of the CoREST corepressor complex, is highly expressed in hematologic malignancies and regulates hematopoietic differentiation. Despite its essential developmental role, LSD1 inhibition has emerged as a promising strategy to enhance retinoic acid (RA)-responsive gene expression in subsets of acute myeloid leukemia (AML). Here, we show that LSD1 physically interacts with RAR/RXR heterodimers at specific genomic loci, restricting chromatin accessibility and transcriptional activation of differentiation programs. Single-agent inhibition of LSD1 or HDACs promotes only partial differentiation. In contrast, Corin, a dual LSD1/CoREST inhibitor, synergizes with all-trans retinoic acid (ATRA) to induce robust myeloid differentiation and apoptosis. Corin treatment alone does not significantly increase H3K4me3 levels; however, in combination with ATRA, it disrupts CoREST-RAR/RXR complexes and facilitates the recruitment of the coactivator p300. Together, they shift chromatin to an active state, enhancing H3K4me3 via increased transcriptional engagement and coactivator recruitment. Our findings identify the functional antagonism between CoREST and p300 as a regulatory axis of RA signaling in AML. Targeting this mechanism with Corin and ATRA re-sensitizes non-APL AML cells to RA-induced differentiation, suggesting a broader therapeutic approach for overcoming resistance in ATRA-refractory leukemias. SignificanceCo-inhibition of LSD1 and HDACs with Corin, combined with ATRA, reprograms chromatin by replacing CoREST with p300, uniquely activating differentiation-associated genes and offering a targeted strategy for treating AML. Graphical abstract created with BioRender (https://biorender.com). O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=139 SRC="FIGDIR/small/682235v1_ufig1.gif" ALT="Figure 1"> View larger version (28K): org.highwire.dtl.DTLVardef@1216c81org.highwire.dtl.DTLVardef@15ac53aorg.highwire.dtl.DTLVardef@4a96d2org.highwire.dtl.DTLVardef@f3caaf_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: ChIP-seq
- assay: DNA methylation
- research focus: drug response / drug discovery
- research focus: differential expression
- research focus: gene regulatory network inference
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Combinatorial inhibition of LSD1 and Menin induces therapeutic differentiation in AML
María F. Carrera Rodríguez, Joshua Rico, … Mario Andres Blanco·bioRxiv·Nov 9, 2025
- Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AML
Mina Masoumeh Tayari, Helena Gomes Dos Santos, … Justin M. Watts·bioRxiv·Oct 13, 2025
- Targeting the SUMO pathway primes all-trans-retinoic acid-induced differentiation of non promyelocytic Acute Myeloid Leukemias
H. Baik, M. Boulanger, … g. bossis·bioRxiv·Jan 29, 2018
- Pharmacological inhibition of LSD1 triggers myeloid differentiation by targeting GSE1, a novel oncogene in AML
L. Nicosia, F. L. Boffo, … T. Bonaldi·bioRxiv·Feb 16, 2021
- HDAC inhibitor derivatives induce differentiation of leukemic cells through two distinct and separable mechanisms
P. Kumar, L. Josa-Cullere, … A. J. Russell·bioRxiv·Jan 6, 2024
- Targeting IL-1/IRAK1/4 signaling in Acute Myeloid Leukemia Stem Cells Following Treatment and Relapse
Tzu‐Chieh Ho, Mark W. LaMere, … Michael W. Becker·LeukemiaPeer-reviewed·Dec 19, 2025